首页|重组人生长激素联合葡萄糖酸钙口服液治疗对矮小症患儿生长发育及骨代谢的影响

重组人生长激素联合葡萄糖酸钙口服液治疗对矮小症患儿生长发育及骨代谢的影响

扫码查看
目的 探讨重组人生长激素联合葡萄糖酸钙口服液治疗矮小症儿童的效果.方法 100例矮小症患儿随机分为两组,参照组予以重组人生长激素治疗,联合组在参照组基础上予以葡萄糖酸钙口服液治疗,比较两组的生长发育、骨代谢指标以及不良反应.结果 治疗6个月后,联合组的身高、体重、骨龄均显著高于参照组,BALP、OC水平均显著高于参照组,β-CTX水平显著低于参照组(P<0.05).两组的不良反应总发生率比较,差异无统计学意义(P>0.05).结论 重组人生长激素联合葡萄糖酸钙口服液治疗矮小症可明显促进患儿生长发育,改善患儿骨代谢水平.
Impact of Recombinant Human Growth Hormone Combined with Calcium Gluconate Oral Solution Treatment on Growth and Development and Bone Metabolism of Children with Dwarfism
Objective To explore the effect of recombinant human growth hormone combined with calcium gluconate oral solution in the treatment of children with dwarfism.Methods 100 children with dwarfism were randomly divided into two groups.The reference group was treated with recombinant human growth hormone,while the combined group was treated with calcium gluconate oral solution on the basis of the reference group.The indicators of growth and development and bone metabolism,and the adverse reactions of the two groups were compared.Results After 6 months of treatment,the height,weight and bone age of the combined group were significantly higher than those of the reference group,the levels of BALP and OC were significantly higher than those of the reference group,and the β-CTX level was significantly lower than that of the reference group(P<0.05).No significant difference was found in the total incidence of adverse reactions between the two groups(P>0.05).Conclusions Recombinant human growth hormone combined with calcium gluconate oral solution in the treatment of dwarfism can significantly promote the growth and development of children,and improve their bone metabolism levels.

Calcium gluconate oral solutionDwarfismGrowth and developmentBone metabolism

冯松叶、乔政维

展开 >

郑州大学第一附属医院药学部,河南郑州 450052

葡萄糖酸钙口服液 矮小症 生长发育 骨代谢

2024

临床医学工程
国家医疗保健器具工程技术研究中心

临床医学工程

影响因子:0.193
ISSN:1674-4659
年,卷(期):2024.31(4)
  • 8